This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Five Dumbest Things on Wall Street This Week: Dec. 14

Stocks in this article: NFLX GRPN HBC SPPI BRK-A

2. Spectrum's Shortsighted CEO

A slew of companies have been issuing special dividends lately due to the impending fiscal cliff. And with 2013 tax rates still unsettled, it's not difficult to understand why companies are doling out cash to investors prior to year's end.

That said, the same solid reasoning can't be applied to the special 15-cent dividend announced by Spectrum Pharmaceuticals (SPPI - Get Report) this past Tuesday. According to TheStreet's biotech ax, Adam Feuerstein, Spectrum CEO Raj Shrotriya is less a dividend play to enthuse loyal shareholders than a dividend ploy to keep short sellers at bay. In fact, Feuerstein asserts that Shrotriya has an unhealthy obsession with the shorts, who now represent about 60% of the company's freely traded shares.

Well, Adam, at least you can't accuse the guy of being paranoid, because with a short count that high, they really are out to get him.

Unfortunately, you can't call him a great CEO either, because based on his firm's recent results, they are out to get him for a pretty good reason indeed. Spectrum posted disappointing third-quarter revenue and sequentially flat product sales figures. Furthermore, the company's 2012 guidance implies paltry 3% revenue growth for the December quarter, which only serves to heighten skepticism over Spectrum's sudden payout. The stock, which popped almost 4% on the news, is down 24% this year and probably would be down even more if the shorts hadn't started piling into it like clowns into a Volkswagon.

"Recent Fusilev sales don't inspire confidence, with $25.4 million in October sales reported by Wolters Kluwer, down from $26.1 million in September, which was down from $29.7 million in August. That's a trend heading in the wrong direction," adds Feuerstein. "Don't forget, too, that Sagent Pharmaceuticals only recently began supplying the market with generic leucovorin, which could be stunting Fusilev growth."

Shrotriya obviously sees things differently from our buddy Adam. Spectrum's CEO released a statement saying that the special dividend is based on the company's "successful growth in revenue and profits this year" and is an "appropriate way to provide an additional return on investment to our many loyal shareholders."

Um, sorry Shotriya, but we don't see much loyalty when it comes to your stock. All we see is a whole lot of folks lending out their shares to people waiting for it to drop.

And if you keep focusing on these silly little tricks to scare them off instead of leading your company, you are only going to prove them right.

4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs